Search - tctmd.com

Displaying 1 - 20 of 59

Sort: Relevancy | Date

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

November 08, 2025

Two Trials Provide Insights Into Catheter Ablation Options for Persistent AF

News Conference News AHA 2024

Two Trials Provide Insights Into Catheter Ablation Options for Persistent AF

November 21, 2024

Extreme Heat Seems to Spark More Atrial Arrhythmias in IED Patients

News Conference News AHA 2024

Extreme Heat Seems to Spark More Atrial Arrhythmias in IED Patients

November 19, 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

News Conference News AHA 2024

Lifestyle and Risk Factors Matter for AF Burden—Metformin May Not: TRIM-AF

November 18, 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

News Conference News AHA 2024

Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD

Yael L. Maxwell

November 16, 2024

For LGBTQ+ Patients With Heart Failure, EMR Details Often Absent

News Conference News AHA 2023

For LGBTQ+ Patients With Heart Failure, EMR Details Often Absent

November 17, 2023

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

News Conference News AHA 2023

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

November 17, 2023

New CVD Risk Tool Can Spur Even Earlier Talk About Prevention

News Conference News AHA 2023

New CVD Risk Tool Can Spur Even Earlier Talk About Prevention

Yael L. Maxwell

November 14, 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

November 13, 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

November 11, 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

November 11, 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

News Conference News AHA 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

November 07, 2023

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

New Tool Assesses Risk in Acute HF Then Suggests Next Steps, Cutting Later Events

News Conference News AHA 2022

New Tool Assesses Risk in Acute HF Then Suggests Next Steps, Cutting Later Events

Yael L. Maxwell

November 07, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

ApoB Gains Ground as Best Lipid Predictor of MI Risk

News Conference News AHA 2021

ApoB Gains Ground as Best Lipid Predictor of MI Risk

Michael O'Riordan

November 22, 2021

Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage

News Conference News AHA 2021

Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage

November 19, 2021

Dietary Patterns, Social Pressures: AHA Offers New Nutrition Advice

News Conference News AHA 2021

Dietary Patterns, Social Pressures: AHA Offers New Nutrition Advice

November 19, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.